SHIFT Newsroom · UK
MHRA Issues Reminder on GLP-1 Receptor Agonists' Potential Side Effects and Misuse
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals of the potential side effects and misuse of GLP-1 receptor agonists.
The MHRA has issued a reminder of the potential side effects and misuse of GLP-1 receptor agonists. This reminder is relevant to the UK as it affects the safety and efficacy of treatments using these medications.
SHIFT’s take
This reminder is relevant to the UK as it affects the safety and efficacy of treatments using GLP-1 receptor agonists, which are used to manage conditions such as type 2 diabetes and obesity.
Known facts
- The MHRA has issued a reminder of the potential side effects and misuse of GLP-1 receptor agonists.